The Zhitong Finance App learned that on September 2, OMass Therapeutics announced that it had reached an exclusive cooperation and licensing agreement with Genentech (Genentech), a member of the Roche Group (RHHBY.US), authorizing the latter to develop and commercialize OMass's preclinical oral small molecule program for inflammatory bowel disease (IBD). OMass is a biotechnology company that develops drugs for highly proven target ecosystems such as membrane proteins or intracellular complexes.

Zhitongcaijing · 09/02/2025 13:25
The Zhitong Finance App learned that on September 2, OMass Therapeutics announced that it had reached an exclusive cooperation and licensing agreement with Genentech (Genentech), a member of the Roche Group (RHHBY.US), authorizing the latter to develop and commercialize OMass's preclinical oral small molecule program for inflammatory bowel disease (IBD). OMass is a biotechnology company that develops drugs for highly proven target ecosystems such as membrane proteins or intracellular complexes.